SCHEMBL83606

SCHEMBL83606

CCCCc1ccc(CCCC)c(O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.69
HTT P42858 2/20 0.62
NPC1 O15118 1/20 0.62
HPGD P15428 1/20 0.62
MAPK1 P28482 1/20 0.62
RAB9A P51151 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
ALOX15 P16050 2/20 0.59
MEN1 O00255 1/20 0.59
TP53 P04637 1/20 0.59
CYP3A4 P08684 1/20 0.59
ALOX5 P09917 1/20 0.59
MAPT P10636 1/20 0.59
TSHR P16473 1/20 0.59
KMT2A Q03164 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
IGF1R P08069 1/20 0.52
PPARA Q07869 1/20 0.51
ESR1 P03372 1/20 0.51
CYP19A1 P11511 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11248095 0.94 TYR (0.69) TYRHTTNPC1HPGDMAPK1
SCHEMBL28793656 0.94 TYR (0.69) TYRHTTNPC1HPGDMAPK1
SCHEMBL5167885 0.94 TYR (0.67) TYRHTTNPC1HPGDMAPK1
SCHEMBL5168590 0.94 TYR (0.61) TYRHTTNPC1HPGDMAPK1
SCHEMBL4960416 0.94 TYR (0.68) TYRHTTNPC1HPGDMAPK1
SCHEMBL4959142 0.92 TYR (0.71) TYRHTTALOX15MEN1TP53
SCHEMBL4957861 0.92 TYR (0.71) TYRHTTALOX15MEN1TP53
SCHEMBL4961630 0.92 TYR (0.71) TYRHTTALOX15MEN1TP53
SCHEMBL4958674 0.92 TYR (0.71) TYRHTTALOX15MEN1TP53
SCHEMBL4960346 0.92 TYR (0.71) TYRHTTALOX15MEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107148433-A Resole curable with functional polyester 伊士曼化工公司 2017-09-08 CN claimed
EP-3212685-A1 RESOLE PHENOLIC RESINS CURABLE WITH FUNCTIONAL POLYESTERS Eastman Chemical Company (US) 2017-09-06 EP claimed
WO-2016069572-A1 RESOLE PHENOLIC RESINS CURABLE WITH FUNCTIONAL POLYESTERS EASTMAN CHEMICAL COMPANY (US) 2016-05-06 WO claimed
US-20160115347-A1 RESOLE PHENOLIC RESINS CURABLE WITH FUNCTIONAL POLYESTERS EASTMAN CHEMICAL COMPANY (US) 2016-04-28 US claimed
CN-120118458-A Curable composition, resin, and cured product 东京应化工业株式会社 2025-06-10 CN disclosed
CN-119937242-A Photosensitive resin composition 东京应化工业株式会社 2025-05-06 CN disclosed
CN-113337170-B Curable composition, cured product, near infrared absorbing filter, and method for producing same 东京应化工业株式会社 2024-04-05 CN disclosed
CN-117327362-A Curable resin composition 东京应化工业株式会社 2024-01-02 CN disclosed
CN-117215149-A Photosensitive resin composition 东京应化工业株式会社 2023-12-12 CN disclosed
CN-113387055-A Film, method for producing film, and bag 住友化学株式会社 2021-09-14 CN disclosed
CN-113337170-A Curable composition, cured product, near-infrared absorption filter, and method for producing same 东京应化工业株式会社 2021-09-03 CN disclosed
CN-102884089-B Process for preparing telechelic polyolefins from terpene initiators 雪佛龙奥伦耐有限责任公司 2018-02-23 CN disclosed
US-6664420-B2 For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia MAGNESIUM DIAGNOSTICS, INC. 2003-12-16 US disclosed
EP-1355638-A2 ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES Magnesium Diagnostics, Inc. (US) 2003-10-29 EP disclosed
CN-1405217-A Polymer electrolyte composition and fuel cell SUMITOMO CHEMICAL CO (JP) 2003-03-26 CN disclosed
US-20030040625-A1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states MAGNESIUM DIAGNOSTICS, INC. 2003-02-27 US disclosed
US-6455734-B1 ADMINISTERING PHENYLGLYCINAMIDE(N-2,4-DIAMYLPENTANOIC ACID AMIDE) AS HYPOTENSIVE AGENTS FOR PROPHYLAXIS OF INSULIN RESISTANCE, ECLAMPSIA AND SENSITIVITY TO BLOOD METAL CONCENTRATIONS MAGNESIUM DIAGNOSTICS, INC. 2002-09-24 US disclosed
WO-2002011714-A2 ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES MAGNESIUM DIAGNOSTICS, INC. (US) 2002-02-14 WO disclosed
EP-0149173-B1 TRIBUTYLPHENOLETHER-GLYCIDYL-SULPHONATES, PROCESS FOR THEIR PREPARATION AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-08 EP disclosed
EP-0149173-A1 Tributylphenolether-glycidyl-sulphonates, process for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1985-07-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040625-A1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states ECE1, PLPBP, ECE2 TYR 4860/4885HTT 3426/4885NPC1 2173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.